Choose your country to see the products for your location

SALSA MLPA Probemix P244 AIP-MEN1-CDKN1B

Multiple endocrine neoplasia (MEN) type1, 4; Pituitary adenoma predisposition syndrome

Region: AIP 11q13.2; MEN1 11q13.1; CDKN1B 12p13.1

MLPA | CE
Intended use: The SALSA MLPA probemix P244 AIP-MEN1-CDKN1B is an in vitro diagnostic (IVD)1 or a research use only (RUO) assay for the detection of deletions or duplications in the AIP, MEN1 and CDKN1B genes in order to confirm a potential cause and clinical diagnosis of familial isolated pituitary adenoma (FIPA), multiple endocrine neoplasia type 1 (MEN1) or multiple endocrine neoplasia type 4 (MEN4), respectively. This product can also be used for molecular genetic testing of at-risk family members.

This assay is for use with human DNA extracted from peripheral blood. In a research setting this assay can be used on DNA extracted from fresh tumour tissue or from formalin-fixed paraffin embedded tumour materials. Deletions or duplications detected with the P244 AIP-MEN-CDKN1B probemix should be confirmed by another technique. In particular, deletions or duplications detected by only a single probe always require confirmation by another method. Most defects in the aforementioned genes are point mutations, none of which will be detected by MLPA. It is therefore recommended to use this SALSA MLPA probemix in combination with sequence analysis of these genes. This assay is not intended to be used as a standalone assay for clinical decisions. The results of this test must be interpreted by a clinical molecular geneticist or equivalent.

1Please note that this probemix is for In Vitro Diagnostic (IVD) use in the countries specified at the end of this product description. In all other countries, the product is for Research Use Only (RUO).

Clinical background: MEN1 is predominantly characterized by the occurrence of primary hyperparathyroidism (PHPT), which occurs in 95-100% of patients; pancreatic neuroendocrine tumours, which occur in 40-75% of patients; and pituitary adenoma, which is found in 30-50% of patients. Most tumours are non-metastasizing, but many can cause striking and serious clinical effects due to the increased secretion of hormones. It is estimated that in the general population 1 to 10 in 100.000 individuals develop MEN1 during their lifetime. Nine out of ten patients diagnosed with MEN1 have the familial form. MEN1 shows dominant autosomal inheritance and the penetrance is >95% by age 40 for confirmed pathogenic mutations. The mean age of death of MEN1 patients is between 50 and 55 years. The single gene associated with MEN1 syndrome is MEN1, which encodes the menin protein. Heterozygous MEN1 pathogenic variants are found in ~90% of familial MEN1 syndrome patients and in ~65% of sporadic cases. Loss of heterozygosity (LOH) of MEN1 is observed in >90% MEN1 tumours suggesting that MEN1 acts as a tumour suppressor gene, in line with the Knudson 2-hit hypothesis for tumorigenesis. Besides point mutations, several deletions involving one or more complete exons in the MEN1 gene have been described (Carroll 2013, Concolino et al. 2016, Lemos and Thakker 2008, Thakker 2014).

Pituitary adenomas (PAs) occur with a frequency of ~1 in 1000 in the general population. Most cases are sporadic, but approximately 5% occur as a familial cancer. The AIP gene encodes aryl hydrocarbon receptor-interacting protein (AIP), a tumour suppressor that is involved in the control of cell proliferation and differentiation. AIP loss of function mutations are found in 15-25% of FIPA cases, inheritance is autosomal dominant, and the average penetrance is: 15-30%, although this may vary greatly. The prevalence of AIP-related FIPA is estimated at 1:100,000. Similar as for MEN1, LOH is frequently observed, suggesting that AIP also acts as a tumour suppressor gene (Cai et al. 2013). Although most known germline AIP mutations are point mutations, several exon deletions have been reported: exon 1-2, exon 2, exon 1-6 (Georgitsi et al. 2008, Igreja et al. 2010).

MEN1 and AIP are located in close proximity on 11q13 and loss of heterozygosity (LOH) in MEN1 and FIPA associated tumours often affects both genes. Apart from tumours in MEN1 and FIPA patients, LOH of this locus also occurs in sporadic cancers, especially in endocrine tissues. As both genes are considered tumour suppressor genes this double loss may contribute to tumorigenesis. Chromosomal losses of the 11q13 chromosomal band have also been found in other cancers, such as cervical cancer and hibernomas (Newsham 1998; Nord et al. 2010).

MEN4 is a distinct MEN type and the symptoms of MEN4 largely overlap with MEN1 (Pellegata et al. 2006). In a small number (estimated at 1-3%) of MEN1 mutation-negative patients fulfilling the diagnostic criteria for MEN1, mutations in CDKN1B have been detected. Extrapolating from this, the prevalence of MEN4 is very low: at most 1:300,000. Like MEN1, MEN4 is primarily characterized by PHPT and PA, but the additional tumours show some differences; tumours in the reproductive organs, and adrenal & renal tumours have been found in MEN4 patients. The only way to distinguish MEN4 from MEN1 is by identification of a pathogenic mutation in CDKN1B. Somatic CDKN1B gene mutations have also been identified in sporadic tumours, but LOH of CDKN1B in MEN4 tumours has not been found.

Note that this probemix does not contain probes for the RET gene, which is associated to MEN2A and MEN2B. Probes for RET are available in the MLPA probemix P169.

More information on MEN1 can be found on https://www.ncbi.nlm.nih.gov/books/NBK1538/.
More information on AIP-related FIPA can be found on https://www.ncbi.nlm.nih.gov/books/NBK97965/.
More information on MEN4 can be found on: https://omim.org/entry/610755.

Probemix content: The SALSA MLPA Probemix P244-D1 AIP-MEN1-CDKN1B contains 42 MLPA probes with amplification products between 129 and 463 nucleotides (nt). This includes 25 probes for the MEN1-AIP region, 5 probes for the CDKN1B region and 12 reference probes that detect autosomal chromosomal targets that have stable copy numbers in the general population and have relatively stable copy numbers in all cancer types. Complete probe sequences and the identity of the genes detected by the reference probes are available online (www.mlpa.com).

This probemix contains nine quality control fragments generating amplification products between 64 and 105 nt: four DNA Quantity fragments (Q-fragments), two DNA Denaturation fragments (D-fragments), one Benchmark fragment, and one chromosome X and one chromosome Y-specific fragment. More information on how to interpret observations on these control fragments can be found in the MLPA General Protocol and online at www.mlpa.com.

Order Items

Probemix

Item no.
Description
Technology
Price
P244-025R
SALSA MLPA Probemix P244 AIP-MEN1-CDKN1B – 25 rxn
€ 243.00
P244-050R
SALSA MLPA Probemix P244 AIP-MEN1-CDKN1B – 50 rxn
€ 486.00
P244-100R
SALSA MLPA Probemix P244 AIP-MEN1-CDKN1B – 100 rxn
€ 972.00

Required Reagents

Item no.
Description
Technology
Price
EK1-FAM
SALSA MLPA EK1 reagent kit – 100 rxn – FAM
€ 300.00
EK1-Cy5
SALSA MLPA EK1 reagent kit – 100 rxn – Cy5
€ 300.00
EK5-FAM
SALSA MLPA EK5 reagent kit – 500 rxn – FAM
€ 1380.00
EK5-Cy5
SALSA MLPA EK5 reagent kit – 500 rxn – Cy5
€ 1380.00
EK20-FAM
SALSA MLPA EK20 reagent kit – 2000 rxn – FAM
€ 5295.00

Related Products

SALSA MLPA Probemix P017 MEN1

Contains the same MEN1 probes as this P244 probemix, but does not contain probes for the AIP gene, CDKN1B gene and several other genes in the 11q13 region.

SALSA MLPA Probemix P169 Hirschsprung-1

Contains probes for the RET gene.

Sign in

Don't have an account? Create one

Forgot password?

Select Your Country

Choose your country to see the products for your location

CE

CE-marked products are for In Vitro Diagnostic (IVD) use only in EU (candidate) member states and members of the European Free Trade Association (EFTA).